Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-104IAR in Knee Osteoarthritis
NCT04120402Phase 2Completed
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of EP-104IAR in osteoarthritis (OA), sponsored by Eupraxia Pharmaceuticals Inc.. Started Sep 2021; status: completed.
02
Drugs
EP-104IAR
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04120402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120402.